Overview

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects

Status:
Completed

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

First in human study to evaluate the safety, tolerability, and pharmacokinetics of PF-03716539. The potential of PF-03716539 to increase the concentrations of midazolam, darunavir and maraviroc will also be evaluated.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Darunavir
Maraviroc
Midazolam